An increased prevalence of metabolic adverse effects in patients with schizophrenia contributes to lower life expectancy and increased rates of mortality; thus, the use of metformin to prevent weight gain and decrease leptin levels can be beneficial in reducing these outcomes and improving the quality of life for those taking olanzapine. Here, LEP is linked to schizophrenia.